Goldman Sachs analyst Rajan Sharma upgraded Genmab (GMAB) to Buy from Neutral with a $30.50 price target The firm sees a “catalyst-rich” 2026 for Genmab and a favorable risk/reward for the shares following a review of the company’s Epkinly, Rina-S and petosemtamab assets. Goldman sees potential $5B-plus in peak sales potential across the three future growth drivers. While the forthcoming Darzalex royalty stream expiration will pressure Genmab’s growth from 2029, this is now appropriately reflected in the shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: Late‑Stage Pipeline De‑Risking and 2026 Catalysts Create Compelling 25% Upside Despite Darzalex LOE Overhang
- Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility
- Genmab Registers AGM-Approved Share Capital Reduction After Cancelling 1.9 Million Treasury Shares
- Genmab Discloses Orbis as New 4.85% Major Shareholder
- Genmab Boosted by Strong Q1 2026 DARZALEX Sales of Nearly USD 4 Billion